Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats

Cai, Wei; Gu, Youyi; Li, Aimin; Cui, Huanqin; Yao, Yi

doi:10.1016/s1995-7645(14)60157-7

Cited by 4 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the histologic features of these two rats were not occurred obvious abnormality after recovery period, which may be because the injury degree was not serious enough to cause pathological changes. Secondly, as we known, the fluctuation range of SD rats' serum CREA is widely, and various among different study reports (Iga et al, 2010 ; Zhao et al, 2011 ; Cai et al, 2014 ). According to these results, although the CREA value (42.2 ± 6.1 μM) was increased in Arctigenin 12 mg/kg group, this difference within normal fluctuation range.…”

Section: Discussionmentioning

confidence: 95%

28-Day Oral Chronic Toxicity Study of Arctigenin in Rats

et al. 2018

View full text Add to dashboard Cite

Arctium lappa (burdock) is the most popular daily edible vegetable in China and Japan because of its general health tonic effects. Previous studies focused on the beneficial role of Arctigenin but neglected its potential side-effects and toxicities. In the present study, the sub-chronic toxicity profile of Arctigenin following 28 days of consecutive exposure was investigated in rats. The results showed that during the drug exposure period, Arctigenin-12 mg/kg administration resulted in focal necrosis and lymphocytes infiltration of heart ventricular septal muscle cells. In the kidney cortical zone, the renal tubular epithelial cells were swollen, mineralized, and lymphocyte infiltrated. In the liver, the partial hepatocyte cytoplasm showed vacuolation and fatty changes, focal necrosis, and interstitial lymphocyte infiltration. In the rats that underwent 36 mg/kg/day administration, there was bilateral testis and epididymis atrophy. In the lung and primary bronchus, erythrocytes and edema fluid were observed. Changes of proestrus or estrus were observed in the uterus, cervix, and vagina intimal epithelial cells. Lymphocytic focal infiltration occurred in the prostate mesenchyme. The high dosage of Arctigenin only decreased the body weight at day 4. At the end of the recovery period, histopathological changes were irreversible, even after withdrawal of the drug for 28 days. Focal necrosis still existed in the heart ventricular septal muscle cells and hepatocytes. Lymphocyte infiltrations were observed in the heart, renal cortex, hepatocyte, and pancreas exocrine gland. Meanwhile, atrophy occurred in the testicles and pancreas. In addition, in the Arctigenin-12 mg/kg group, creatinine (CREA) and brain weight were both significantly increased. The toxicokinetical study demonstrated that Arctigenin accumulated in the organs of rats. The food consumption, hematological, and biochemical parameters were not associated with the above results. These contradictory results might result from the lesions induced by Arctigenin, which were not sufficiently serious to change the parameters. These results suggest that Arctium lappa should be consumed daily with caution because of the potential toxicity induced by Arctigenin. According to all results, the lowest observed adverse effect level (LOAEL) was induced by 12 mg/kg daily exposure to Arctigenin, and the No-observed-adverse-effect-level (NOAEL) should be lower than 12 mg/kg.

show abstract

Section: Discussionmentioning

confidence: 95%

28-Day Oral Chronic Toxicity Study of Arctigenin in Rats

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Studies have shown that PGE1 can dilate renal vessels, increase renal blood flow, and increase CrCl, which has a protective effect on renal function, and then prevent the occurrence and development of CIN. 21 Its main renal protective effect is to dilate renal vessels, inhibit platelet aggregation, and achieve renal vascular relaxation balance without systemic hypotension. 22,23 Prostaglandin E1 exerts an effect through nonspecific, dose-dependent, reversible indirect inhibition of lymphokine-mediated actions.…”

Section: Discussionmentioning

confidence: 99%

The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score

Liu

Zhang

et al. 2021

Angiology

View full text Add to dashboard Cite

The Mehran risk score (MRS) was used to classify patients with coronary heart disease and evaluate the preventive effect of alprostadil on contrast-induced nephropathy (CIN) after percutaneous coronary intervention. The patients (n = 1146) were randomized into an alprostadil and control group and then divided into 3 groups on the basis of the MRS: low-risk, moderate-risk, and high-risk groups. The primary end point was the occurrence of CIN (alprostadil + hydration vs simple hydration treatment); secondary end points included serum creatinine, blood urea nitrogen, creatinine clearance rate, cystatin C, interleukin-6, C-reactive protein, proteinuria, and differences in the incidence of major adverse events. In the low-risk, moderate-risk, and high-risk groups, the incidence of CIN in the control and alprostadil group was 2.9 versus 2.6% ( P = .832), 11.4 versus 4.9% ( P = .030), 19.1 versus 7.7% ( P = .041), respectively. Multivariate logistic regression analysis showed that alprostadil treatment was a favorable protective factor for moderate-risk and high-risk CIN patients (OR = 0.343, 95% CI: 0.124-0.951, P = .040). Alprostadil can be used as a preventive treatment for moderate- and high-risk CIN patients classified by the MRS. The reduction of CIN by alprostadil may be related to an anti-inflammatory effect.

show abstract

“…[8][9][10][11] The main component of alprostadil is prostaglandin E1 (PGE1), which is blood vessel-expanding agent that can dilate kidney and renal blood vessels, increases renal blood flow, inhibits platelet aggregation, prevents renal microvascular thrombosis, reduces renal blood viscosity, inhibits inflammatory mediators, maintains renal perfusion, and reduces urinary protein synthesis. 12,13 Some animal studies have shown that PGE1 has a protective effect on renal by reducing the number of NF-kBþ, caspase-3þ inflammatory cells, and NF-kB DNAbinding activity; increasing proliferating cell nuclear antigenþ epithelial cells; inhibiting the expression of intracellular adhesion molecule 1; ameliorating the renal microvascular injury; relieving hypoxia; and protecting renal function. [17][18][19] Therefore, alprostadil may be a new drug to prevent the occurrence of CIN.…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10][11] Alprostadil, a potent renal dilatator, has some protective effects on renal function, such as expanding renal blood vessels, increasing renal blood flow, inhibiting platelet aggregation, protecting vascular endothelial cells, reducing vasoconstrictor effect, stabilizing lysosomal membranes, decreasing blood viscosity and erythrocyte aggregation, and improving erythrocyte deformability, which may be beneficial in reducing CIN. 12,13 Some studies showed that alprostadil plays a prophylactic role in the development of CIN, 14,15 but most of the studies were single center and of small sample size, so the exact preventive role of alprostadil in CIN remains unclear. Therefore, the purpose of this study is to investigate whether alprostadil could reduce the incidence of CIN in patients with renal insufficiency undergoing PCI.…”

Section: Introductionmentioning

confidence: 99%

Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention

Yang

Zhang

et al. 2017

Angiology

View full text Add to dashboard Cite

We investigated the preventive effect of alprostadil on contrast-induced nephropathy (CIN) in patients with renal insufficiency undergoing percutaneous coronary intervention (PCI). A total of 300 patients with creatinine clearance (crCl) ≤60 mL/min undergoing PCI were randomly assigned to alprostadil or a control group. The primary end point was the incidence of CIN defined as an increase in serum creatinine (Scr) levels by ≥0.5 mg/dL or≥ 25% after administration of the contrast media within 72 hours. The secondary end points were (1) changes in Scr and crCl within 72 hours and (2) the incidence of major adverse events during hospitalization. The incidence of CIN was 2.7% (4/150) in the alprostadil group, and 8.7% (13/150) in the control group (χ = 5.05, P = .043).There was no difference regarding the incidence of major adverse events during hospitalization between the alprostadil group and control groups (2.7% vs 4.0%, P = .750). Multivariate logistic regression analysis showed that alprostadil was an independent protective factor for CIN (odds ratio = 0.136, 95% confidence interval: 0.020-0.944, P = .044). Prophylactic administration of alprostadil may prevent CIN in patients with renal insufficiency undergoing PCI.

show abstract

Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats

Abstract: Alprostadil combined with diammonium glycyrrhizinate can significantly lower the expression of TGF - β1 and CTGF in serum and tissues of SD rat with renal interstitial fibrosis, thus inhibit rat renal interstitial fibrosis process. It has synergy protective effect.

Cited by 4 publications

References 13 publications

28-Day Oral Chronic Toxicity Study of Arctigenin in Rats

28-Day Oral Chronic Toxicity Study of Arctigenin in Rats

The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score

Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention

Contact Info

Product

Resources

About